AGE stock forecast
Our latest prediction for AgeX Therapeutics, Inc.'s stock price was made on the April 1, 2020 when the stock price was at 0.80$.
In the short term (2weeks), AGE's stock price should outperform the market by 7.59%. During that period the price should oscillate between -12.16% and +28.47%.
In the medium term (3months), AGE's stock price should outperform the market by 24.83%. During that period the price should oscillate between -35.82% and +72.24%.Get email alerts
Create a solid portfolio with AGE
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc. operates as a biotechnology company. The firm focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its technology platforms include PureStem, UniverCyte, iTR and HyStem. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -0.32$ per share.
The book value per share is 0.18$
Three months stock forecastApril 1, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|